Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. is a leading biotechnology company founded in 2014, headquartered in Cambridge, Massachusetts. The company specializes in developing gene-editing technologies based on CRISPR/Cas9 systems to create treatments for genetic diseases. Under the leadership of CEO John Leonard, Intellia aims to harness the revolutionary potential of CRISPR-based therapies to address diseases with significant unmet medical need. As of recent reports, the company continues to advance its robust pipeline of in vivo and ex vivo therapeutic candidates. Intellia's innovative approach and strategic partnerships have positioned it as a prominent player in the gene-editing field.